CV Sciences operates two distinct divisions: pharmaceuticals and consumer products. These divisions are supported by our medical and scientific advisory board, and state-of-the art production facilities.

News Releases

News Releases

CV Sciences, Inc. Announces Webcast for Investor Update Call

Webcast information provided for call on September 12th at 1:15pm PT/4:15pm ET LAS VEGAS, NV–(Marketwired – September 11, 2017) – CV Sciences, Inc., (OTCQB: CVSI) (the “Company,” “CV Sciences,” “our” or “we”) has provided a webcast for the Company’s shareholder update call on Tuesday, September 12, 2017 at 1:15 PM PT/4:15PM ET. CV Sciences’ President and … Continue reading CV Sciences, Inc. Announces Webcast for Investor Update Call

CV Sciences, Inc. to Host Investor Update Call

Company to Provide Updates to Shareholders and Prospective Investors on September 12th at 1:15pm PT/4:15pm ET LAS VEGAS, NV–(Marketwired – September 6, 2017) – CV Sciences, Inc., (OTCQB: CVSI) (the “Company” or “CV Sciences”), market-leading supplier and manufacturer of hemp-derived cannabidiol (CBD) consumer products and developer of specialty pharmaceutical therapeutics, today announced that it will host a shareholder update … Continue reading CV Sciences, Inc. to Host Investor Update Call

CV Sciences, Inc. to Exhibit its Industry Dominating Hemp-derived CBD Brand, PlusCBD Oil™, at Natural Products Expo East 2017 in Baltimore, Maryland

Company enters its 3rd year sponsoring and exhibiting at the nation’s second largest natural products trade show, offering natural health retailers show specials, one-on-one education, and a wide selection of product offerings LAS VEGAS, NV–(Marketwired – September 05, 2017) – CV Sciences, Inc. (OTCQB: CVSI), preeminent supplier and manufacturer of hemp-derived phytocannabinoids including CBD oil, announced today that … Continue reading CV Sciences, Inc. to Exhibit its Industry Dominating Hemp-derived CBD Brand, PlusCBD Oil™, at Natural Products Expo East 2017 in Baltimore, Maryland

CV Sciences, Inc. to Present at MJAC2017 InvestorsHub International Cannabis Conference

LAS VEGAS, NV–(Marketwired – August 28, 2017) – CV Sciences, Inc. (OTCQB: CVSI) (“CV Sciences,” “our” or “we”), is pleased to announce today that they will be presenting at the MJAC2017 InvestorsHub International Cannabis Conference in Los Angeles, California on September 1-2, 2017 at the JW Marriott L.A. Live. CV Sciences will exhibit at Conference booth #308 … Continue reading CV Sciences, Inc. to Present at MJAC2017 InvestorsHub International Cannabis Conference

CV Sciences, Inc. Cites Additional Research to Support Role of Cannabidiol in Overcoming Drug Addictions

New Research Evidencing the Role of CBD to Inhibit the Establishment of Drug Reward With Morphine LAS VEGAS, NV–(Marketwired – August 23, 2017) – CV Sciences, Inc., (OTCQB: CVSI) (the “Company,” “CV Sciences,” “our” or “we”), today cited additional research suggesting cannabidiol (CBD) may be efficacious in preventing and treating drug addictions. A recent study conducted by … Continue reading CV Sciences, Inc. Cites Additional Research to Support Role of Cannabidiol in Overcoming Drug Addictions

CV Sciences, Inc. Highlights Recent Research Showing Cannabidiol May Reduce Relapses in Smokeless Tobacco Addiction

LAS VEGAS, NV–(Marketwired – August 15, 2017) – CV Sciences, Inc. (OTCQB: CVSI) (the “Company,” “CV Sciences,” “our” or “we”) highlighted a recent study conducted at Federal University of Prana and Santa Catarina in Brazil which reports that preclinical and clinical studies suggested that cannabidiol (CBD) may help prevent drug addiction relapse. The research cites the effects of CBD drugs … Continue reading CV Sciences, Inc. Highlights Recent Research Showing Cannabidiol May Reduce Relapses in Smokeless Tobacco Addiction

CV Sciences, Inc. Announces its Title Sponsorship of the 24th Annual Hemp Industries Association 2017 National Conference

Company to Exhibit and Present amongst Fellow Hemp Industry Leaders, Furthering its Dedication to Advancing Hemp Research, Education and Quality Consumer Products LAS VEGAS, NV–(Marketwired – August 09, 2017) – CV Sciences, Inc. (OTCQB: CVSI) (the “Company,” “CV Sciences,” “our” or “we”), today announced its Title Sponsorship of the 24th Annual Hemp Industries Association Conference (HIACON), held on September … Continue reading CV Sciences, Inc. Announces its Title Sponsorship of the 24th Annual Hemp Industries Association 2017 National Conference

CV Sciences, Inc. Cites Research Suggesting Possible Therapeutic Role for Cannabidiol in Alzheimer’s and Parkinson’s Diseases

Discovery of Novel Molecular Targets for Neurodegenerative Diseases LAS VEGAS, NV–(Marketwired – August 01, 2017) – CV Sciences, Inc., (OTCQB: CVSI) (the “Company,” “CV Sciences,” “our” or “we”), cited a recent study conducted by researchers at the University of Louisville School of Medicine suggesting a scientific basis for the potential of cannabidiol (CBD) to have therapeutic value … Continue reading CV Sciences, Inc. Cites Research Suggesting Possible Therapeutic Role for Cannabidiol in Alzheimer’s and Parkinson’s Diseases

CV Sciences, Inc. Hosts Lunch Seminar at National University of Natural Medicine 2017 Medical Cannabis Conference

Company Enters its Second Year Sponsoring Continuing Education for University Students, Alumni, and Local Practitioners Interested in Learning More about Cannabis-Related Research and Methodologies LAS VEGAS, NV–(Marketwired – July 25, 2017) – CV Sciences, Inc., (OTCQB: CVSI) (the “Company,” “CV Sciences,” “our” or “we”), preeminent supplier and manufacturer of hemp-derived cannabidiol (CBD) oil bulk and consumer products, today … Continue reading CV Sciences, Inc. Hosts Lunch Seminar at National University of Natural Medicine 2017 Medical Cannabis Conference

CV Sciences, Inc. Cites Recent Clinical Study on Pharmaceutical-Grade CBD Shown to Lower Blood Pressure

Company Gaining Traction with Drug Candidate CVSI-007 to Become the Only FDA Approved Treatment for Smokeless Tobacco Addiction LAS VEGAS, NV – (Marketwired – July 20, 2017) – CV Sciences, Inc. (OTCQB: CVSI) (the “Company,” “CV Sciences,” “our” or “we”), highlights a recent clinical study using pharmaceutical grade cannabidiol (CBD) which suggests that CBD may … Continue reading CV Sciences, Inc. Cites Recent Clinical Study on Pharmaceutical-Grade CBD Shown to Lower Blood Pressure